ABT240719C60000
- 46.16
- 0.000.00%
Abbott Laboratories Newsroom
Morgan Stanley Maintains Abbott Laboratories(ABT.US) With Hold Rating, Maintains Target Price $107
Morgan Stanley analyst Patrick Wood maintains $Abbott Laboratories(ABT.US)$ with a hold rating, and maintains the target price at $107.According to TipRanks data, the analyst has a success rate of 56.
Abbott Laboratories (ABT) Gets a Hold From Morgan Stanley
Stocks Gain Pre-Bell Ahead of Key Earnings; Asia Mixed, Europe Down
US benchmark equity indexes were trending upwards before the opening bell Monday as traders await earnings from some major companies.Standard & Poor's 500 gained 0.4%, while the Nasdaq and the Dow
Options Volatility: Navigating Big Banks, Healthcare, and Tech Earnings
The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
Goldman Sachs, Netflix, Domino's Pizza, TSMC, and More Stocks to Watch This Week -- Barrons.com
By Nicholas Jasinski Second-quarter earnings season will be investors' main focus this week. Around 50 S&P 500 companies are scheduled to report. BlackRock and Goldman Sachs will be Monday's
Financial Stocks Deliver Profits in Q2 Amid Rebound in Investments - Earnings Scorecard
Abbott Laboratories To Go Ex-Dividend On July 15th, 2024 With 0.55 USD Dividend Per Share
July 11th (Eastern Time) - $Abbott Laboratories(ABT.US)$ is trading ex-dividend on July 15th, 2024.Shareholders of record on July 15th, 2024 will receive 0.55 USD dividend per share on August 15th, 20
Here's How Abbott (ABT) Is Placed Ahead of Q2 Earnings Release
The price of West Texas Intermediate (WTI) crude oil is trading at more than the $80 per barrel mark and is likely to remain strong this year.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
TD Cowen analyst Josh Jennings maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 52.3%
Buy Rating Affirmed for Abbott Laboratories Amidst Strong Growth and Manageable Risks
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 20.24% since its last report. The company recently reported that it has 11.62 million shares sold short, which is 0.67% of all
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121
Abbott Laboratories (ABT) has an average rating of outperform and price targets ranging from $104 to $143, according to analysts by Capital IQ.Price: 101.72, Change: +0.08, Percent Change: +0.08
Susudu Zhilian's IPO is terminated by the Shenzhen Stock Exchange. The company is a comprehensive full-service e-commerce operation service provider.
On July 9th, Peking Shuju Zhilian Technology Co., Ltd. (referred to as Shuju Zhilian) terminated its IPO on the Shenzhen Stock Exchange Growth Board.
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo analyst Larry Biegelsen maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $133.According to TipRanks data, the analyst has a success rate of 58.3
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
Is Abbott Laboratories (ABT) a Good Dividend Growth Stock to Buy and Hold According to Hedge Funds?
TorHoerman Law Advocates for Infants in Pivotal Missouri NEC Trial Against Formula Manufacturers
ST. LOUIS, July 3, 2024 /PRNewswire/ -- TorHoerman Law is set to begin trial on July 8, 2024, in Missouri state court. The case will focus on allegations that cow milk-based baby formula is linked to
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
7 Analysts Have This To Say About Abbott Laboratories
Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table provides a quick overview of their recent ratings